CN112245417A

CN112245417A - Application of metformin in preparation of drug for treating methamphetamine addiction intestinal micro-ecological disorder

Info

Publication number: CN112245417A
Application number: CN202011133129.1A
Authority: CN
Inventors: 杨继青; 王昆华; 张尊月; 熊普; 田维伟; 周勇; 徐玉
Original assignee: First Affiliated Hospital of Kunming Medical University
Current assignee: First Affiliated Hospital of Kunming Medical University
Priority date: 2020-10-21
Filing date: 2020-10-21
Publication date: 2021-01-22

Abstract

The invention discloses an application of metformin in preparation of a drug for treating methamphetamine-addiction intestinal microecological disorder, belonging to the technical field of medicines. The intestinal micro-ecological disorder caused by the addiction of the melbine reversible methamphetamine can be used for preventing and treating intestinal dysbacteriosis, diarrhea and constipation, intestinal inflammation and other accompanying symptoms caused by the addiction of the methamphetamine; lays a foundation for preparing the medicine for preventing and treating the digestive tract diseases and the intestinal barrier injury caused by the methamphetamine addiction.

Description

Application of metformin in preparation of drug for treating methamphetamine addiction intestinal micro-ecological disorder

Technical Field

The invention relates to an application of metformin in preparation of a drug for treating methamphetamine addiction intestinal microecological disorder, belonging to the technical field of medicines.

Background

Methamphetamine (Meth), commonly known as Methamphetamine, is the first drug most frequently ingested in our country. The drug addiction to the ice toxin is often accompanied by the damage of various organs and systems of the body, but the mechanism is unknown, and no effective and reasonable withdrawal method and drug are available at home and abroad.

In clinical practice, intestinal diseases such as peptic ulcer, necrosis, perforation, diarrhea and constipation caused by methamphetamine addiction are very common, and animal experiments show that the damage of methamphetamine to the intestinal barrier is a scientific and clinical problem which needs urgent attention. Our previous studies have found that the composition and abundance of intestinal microecology of methamphetamine addicts are altered and that these changes are closely related to the clinical symptoms described above.

Metformin (Met) is a first-line drug for the treatment of diabetes because of its advantages of safety, low cost, effectiveness, and the like. In recent years, clinical benefits of long-term use of metformin have been discovered, mainly including: reducing cancer risk, reducing weight, resisting aging, preventing haze, assisting in quitting smoking, resisting inflammation, promoting hair growth, improving polycystic ovary syndrome, protecting cardiovascular system, and improving intestinal flora. Whether the metformin can improve the intestinal micro-ecological disorder of methamphetamine addicts or not has no research report at home and abroad.

Disclosure of Invention

The invention aims to provide application of metformin in preparation of a medicament for treating methamphetamine-addicted intestinal micro-ecological disorder.

Preferably, the application of the metformin in preparing the medicament for treating the methamphetamine-addicted intestinal micro-ecological disorder is characterized in that: the metformin and other auxiliary materials acceptable by other human bodies are prepared into capsules, pills, powder, tablets, granules, oral liquid or injection.

The dosage of the metformin provided by the invention is as follows: 200 mg/Kg.

Compared with the prior art, the invention has the following beneficial effects: the application of the metformin to prevention and/or treatment of methamphetamine addiction intestinal micro-ecological disorder is discovered for the first time.

Drawings

Figure 1 is a graph showing the results of metformin reversing methamphetamine addicted gut microbiome composition and abundance.

FIG. 2 is a graph showing the improvement in the levels of enteric microorganisms of Class (Family), Genus (Genus) in mice addicted to methamphetamine by metformin.

Detailed Description

The present invention is further described in detail with reference to the following specific examples, but the scope of the present invention is not limited to the above description.

Example 1

Metformin improves intestinal micro-ecological disorder of methamphetamine addicted mice

1. Experimental animals: kangmason C57/BL mice, 25g in weight, were purchased from Schlekstaka laboratory animals Co., Ltd, Hunan, at 6-8 weeks of age. Animals were housed in independent micro-barrier systems, given 12 hours of alternating light and dark illumination in the recommended temperature and humidity environment, given free water and food.

2. The adopted medicines are as follows: metformin (purchased from Sigma-Aldrich, USA) with a methamphetamine purity of 98%, (supplied by public office of Yunnan province).

Preparation and dosage of metformin: 2.0g of metformin is dissolved in 80 ml of physiological saline for injection, and C57/BL mice with the weight of 25g are injected intraperitoneally, so that the metformin interference dose of 200mg/Kg is obtained.

Preparation and dosage of methamphetamine: 51.02mg of methamphetamine with the purity of 98% is dissolved in 40 ml of normal saline for injection, and 0.2ml of methamphetamine is injected into the abdominal cavity of a mouse with the weight of 25 g.

3. Experiment grouping

The mice were divided into 4 groups, namely a Control group (Control), a methamphetamine (Meth), a methamphetamine and metformin group (Meth + Met), and a metformin group (Met), each group consisting of 10 mice.

4. Experimental protocol

Adapting to the breeding environment on days 1-7;

days 8-28, Control group (Control): injecting 0.2ml of normal saline into the abdominal cavity every day; methamphetamine group (Meth): intraperitoneal injection of 0.2ml Meth is performed every day; methamphetamine and metformin (Meth + Met) groups, i.e., 0.2ml Meth after 3 hours of intraperitoneal injection, 0.2ml Met; metformin group (Met): daily intraperitoneal injections of 0.2ml Met were given.

And on the 29 th day, the mouse feces are collected according to standard operation and then are frozen in liquid nitrogen, and the 16s intestinal microbial sequencing is completed by Shenzhen medical inspection Limited of the Huada gene.

5. Results of the experiment

As shown in figure 1, the composition abundance and diversity of intestinal microorganisms of a methylaniline-addicted mouse (Meth) are changed relative to a normal group mouse (Control), and the abundance and diversity of intestinal flora are improved after 200mg/kg of metformin is intraperitoneally injected.

As shown in figure 2, the intestinal flora of mice addicted to methamphetamine is changed in the levels of family, order and genus, and the flora is recovered after the metformin dry prognosis.

The application of metformin in preventing and/or treating methamphetamine-addiction intestinal micro-ecological disorder is the first discovery of the inventor, and the application of metformin in preventing and treating methamphetamine-addiction intestinal micro-ecological disorder by using metformin alone or in combination is in the protection range of the invention.

Claims

1. Application of metformin in preparing medicine for treating intestinal micro-ecological disorder of methamphetamine addiction is provided.

2. Use of metformin according to claim 1 for the preparation of a medicament for the treatment of methamphetamine-addicted intestinal micro-ecological disorders, characterized in that: the metformin and other auxiliary materials acceptable by other human bodies are prepared into capsules, pills, powder, tablets, granules, oral liquid or injection.